#USA #H.I.G. Capital #Soleo Health #Court Square Capital #Frisco, TX

H.I.G. Capital's Strategic Sale of Soleo Health

On February 3, 2025, H.I.G. Capital, a prominent global alternative investment firm with $67 billion under management, announced a pivotal move in the healthcare sector by selling Soleo Health, a leading infusion platform, to funds managed by Court Square Capital and WindRose Health Investors. This transaction not only highlights H.I.G.'s strategic foresight in the market but also reflects the growing importance of specialized healthcare services in today’s medical landscape.

A Look at Soleo Health

Headquartered in Frisco, Texas, Soleo Health has emerged as a vital provider in the realm of infusion therapy. The company operates an extensive network of 26 pharmacies along with over 30 ambulatory infusion suites scattered across the United States, catering to patients with complex, rare, and ultra-rare medical conditions. With its comprehensive pharmacy licensure, Soleo Health delivers personalized healthcare solutions to patients in all 50 states.

The company's business model is structured around providing specialized care through a mix of pharmacy and home infusion services, which has positioned it strongly within the industry. Its commitment to patient care and innovative therapy-specific clinical approaches distinguishes Soleo as an exceptional player in the healthcare sector.

Growth during H.I.G. Capital's Ownership

Throughout its ownership, H.I.G. Capital played an important role in shaping Soleo Health into a market leader. Key strategies included expanding Soleo's operational footprint with new pharmacy openings and infusion suite setups. H.I.G. also prioritized the diversification of payer relationships and therapy offerings, ensuring the company could respond dynamically to market demands.

Drew Walk, President and CEO of Soleo Health, expressed gratitude towards H.I.G., stating, “H.I.G. has been an exceptional partner, instrumental in helping us build the company into the market leader we are today.” Their collaborative efforts led to significant investments in both talent and infrastructure, ultimately allowing Soleo Health to reach and care for a larger patient base.

Scott Zhu, a Managing Director at H.I.G., recognized the transformational efforts of Drew Walk and his team, praising their journey from a regional player to a powerhouse in national specialty care. “Soleo is an exceptional infusion platform led by a best-in-class leadership team,” he remarked, emphasizing the vast growth potential that lies ahead post-acquisition.

The Vision Ahead for Soleo Health

Soleo Health's future under the new management is expected to build upon the solid foundation established during H.I.G.'s tenure. With an experienced team of clinical pharmacists, registered nurses, and patient care specialists, the company aims to continue delivering comprehensive patient care solutions while enhancing the value it provides in a competitive market.

The company is accredited by notable organizations, such as URAC and the Joint Commission, and holds distinctions in Rare Diseases and Orphan Drugs, reinforcing its credibility and commitment to quality healthcare delivery. Moving forward, Soleo Health is poised to leverage its established infrastructure to expand access to vital infusion therapies and support an even broader range of patients.

Conclusion

The sale of Soleo Health by H.I.G. Capital marks a significant development not just for the company but also for the healthcare sector at large. As the need for specialized healthcare services continues to rise, Soleo is positioned to lead in innovation and service delivery. The combination of strategic investment and operational expertise will likely propel the company into its next phase of growth, and stakeholders will eagerly anticipate the new possibilities that await under Court Square Capital and WindRose Health Investors.